BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...refractory chronic coughA 45 mg dose of P2X3...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...count patients. Bellus also plans to start a Phase II trial this half of the P2X3...
...GnRH/LHRH receptor OX1R (HCRTR1) - Orexin 1 receptor OX2R (HCRTR2) - Orexin 2 receptor P2X3...
BioCentury | Mar 19, 2020
Product Development

March 18 Quick Takes: Duo of Phase III data for Pfizer; plus Sage, Allergan-AbbVie, Merck, DermTech, Beijing Tide-Insilico

...MK-7264) met the primary endpoint in adult patients with treatment-refractory or unexplained chronic cough. The P2X3...
...“CTFH Latest to Partner with Insilico” ). Targets IL-23 - Interleukin-23 JAK-1 - Janus kinase-1 P2X3...
...3 TERT - Telomerase reverse transcriptase BioCentury Staff Allergan Inc. AbbVie Inc. Merck & Co. Inc. Sage Therapeutics Inc. Pfizer Inc. Interleukin-23 (IL-23) Purinergic receptor P2X ligand-gated ion channel 3 (P2X3) Telomerase...
BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

...million, are Jefferies, Cowen, Guggenheim, Baird and Bloom Burton. The company's BLU-5937, a small molecule P2X3...
...diagnosed with and at risk for Type II diabetes. Targets: ALOX12 (12-LOX) - Arachidonate 12-lipoxygenase; P2X3...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...that would give it a dual listing. The company's BLU-5937, a small molecule antagonist of purinergic receptor P2X ligand-gated ion channel 3 (P2X3)...
BioCentury | Jun 20, 2019
Company News

Beyond Keytruda: Merck details plans for future growth

...inhibitor. A third program highlighted by Merck was gefapixant (MK-7264), a purinergic receptor P2X ligand-gated ion channel 3 (P2X3) receptor antagonist. The P2X3...
...around CEO succession timing, Merck said at the time. Targets: DPP-4 (CD26) - dipeptidyl peptidase-4; P2X3...
BioCentury | Dec 15, 2017
Financial News

Bellus Health raises C$20M in follow-on

...cough. Bellus Health has exclusive, worldwide rights to the selective small molecule antagonist of the purinergic receptor P2X ligand-gated ion channel 3 (P2X3)...
...receptor from the Neomed Institute (Montreal, Quebec). Bellus Health Inc. (TSX:BLU), Laval, Quebec Jennie Walters BLU-5937 Bellus Health Inc. P2X3 Purinergic receptor P2X ligand-gated ion channel 3 (P2X3)...
BioCentury | Jun 13, 2016
Company News

Afferent, Merck deal

...in clinical and commercialization milestones for candidates in Afferent’s pipeline, including AF-219 . AF-219, a purinergic receptor P2X ligand-gated ion channel 3 (P2X3)...
...exclusive, worldwide rights from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) to develop and commercialize the pharma’s P2X3...
BioCentury | Jun 10, 2016
Top Story

Merck acquiring Afferent

...Afferent's chronic cough candidate AF-219 , a purinergic receptor P2X ligand-gated ion channel 3 ( P2X3...
BioCentury | Jan 18, 2016
Clinical News

AF-130: Phase I started

...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: AF-130 Business: Cardiovascular Molecular target: Purinergic receptor P2X ligand-gated ion channel 3 (P2X3) Description: Second generation purinergic receptor P2X ligand-gated ion channel 3 (P2X3)...
Items per page:
1 - 10 of 38